Merck Receives FDA Approval for Capvaxive Pneumococcal Vaccine for Adults

Merck today announced that the FDA has approved Capvaxive (V116) 21-valent pneumococcal conjugate vaccine for active immunization to prevent invasive pneumococcal disease and pneumococcal pneumonia in adults 18 years and older. Capvaxive covers 21 pneumococcal serotypes, including 8 serotypes not covered by other approved pneumococcal vaccines. In clinical trials, Capvaxive demonstrated robust immune responses against all 21 serotypes. The approval of Capvaxive provides adults with a new option for pneumococcal vaccination that covers additional serotypes responsible for a significant proportion of pneumococcal disease in adults.